Search

Your search keyword '"Reimitz, P. -E."' showing total 36 results

Search Constraints

Start Over You searched for: Author "Reimitz, P. -E." Remove constraint Author: "Reimitz, P. -E."
36 results on '"Reimitz, P. -E."'

Search Results

1. Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program

3. Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program

4. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study

5. Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF

6. Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program

7. P4785Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program

8. P4788One-year outcomes of elderly patients with atrial fibrillation: snapshot data from the global noninterventional program on edoxaban treatment in routine clinical practice in atrial fibrillation

19. Recovery of left ventricular function after myocardial infarction can be predicted immediately after thrombolysis by semiquantitative intracoronary thallium and technetium pyrophosphate scintigraphy.

20. Relationship between myocardial norepinephrine content and left ventricular function — an endomyocardial biopsy study.

23. Mirtazapine versus amitriptyline in the longterm treatment of depression

25. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

29. Selecting investigators for a placebo controlled clinical trial: The most critical decision point?

30. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.

31. [Guidelines for carrying out application studies in psychopharmacotherapy. "Phase IV Research" Study Group of the Society of Neuropsychopharmacology and Pharmacopsychiatry].

32. [Performance of a rescue breathing device with glossopalatinal tube].

33. [Sexual side effects of H2-receptor antagonists: what is safe?].

34. [Morphologic findings in dilated cardiomyopathy and their relation to hemodynamics and catecholamine concentrations in the plasma and myocardium].

35. [Clinical recognition of early forms of malignant melanoma].

36. [Myocardial noradrenaline content: a factor not considered up to now for the prognosis of patients with dilated cardiomyopathy].

Catalog

Books, media, physical & digital resources